{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:37:33Z","timestamp":1793763453319,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T00:00:00Z","timestamp":1513900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.vaccine.2017.12.034","type":"journal-article","created":{"date-parts":[[2017,12,23]],"date-time":"2017-12-23T15:11:18Z","timestamp":1514041878000},"page":"698-706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study"],"prefix":"10.1016","volume":"36","author":[{"given":"Khalequ","family":"Zaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh Farzana","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1397-677X","authenticated-orcid":false,"given":"Farzana","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayeed-Bin","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Traskine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Ahsan","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ruiz-Gui\u00f1az\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Borys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.12.034_b0005","first-page":"129","article-title":"Pneumococcal vaccines WHO position paper\u20132012","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2017.12.034_b0010","unstructured":"International Vaccine Access Center. Pneumonia & diarrhea progress report: reaching goals through action and innovation; 2016. Available at: <http:\/\/www.jhsph.edu\/research\/centers-and-institutes\/ivac\/resources\/IVAC-2016-Pneumonia-Diarrhea-Progress-Report.pdf> [last accessed: 22.06.2017]."},{"key":"10.1016\/j.vaccine.2017.12.034_b0015","unstructured":"Gavi the Vaccine Alliance. Advance market commitment for pneumococcal vaccines: annual report, 1 April 2014\u201331 March 2015; 2015."},{"key":"10.1016\/j.vaccine.2017.12.034_b0020","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(12)61854-6","article-title":"Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial","volume":"381","author":"Palmu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.12.034_b0025","doi-asserted-by":"crossref","first-page":"e1001657","DOI":"10.1371\/journal.pmed.1001657","article-title":"Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial","volume":"11","author":"Tregnaghi","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2017.12.034_b0030","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.vaccine.2015.06.104","article-title":"Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada","volume":"34","author":"De Wals","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.034_b0035","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1016\/j.vaccine.2015.04.005","article-title":"Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada","volume":"33","author":"Deceuninck","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.034_b0040","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-2600(14)70060-8","article-title":"Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study","volume":"2","author":"Domingues","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2017.12.034_b0045","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1016\/j.vaccine.2015.10.007","article-title":"Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group. Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease","volume":"33","author":"Verani","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.034_b0050","doi-asserted-by":"crossref","first-page":"e0120290","DOI":"10.1371\/journal.pone.0120290","article-title":"Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children \u2013 a population-based study","volume":"10","author":"Jokinen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.12.034_b0055","doi-asserted-by":"crossref","first-page":"e0172690","DOI":"10.1371\/journal.pone.0172690","article-title":"Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study","volume":"12","author":"Palmu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.12.034_b0060","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S2214-109X(14)70224-4","article-title":"Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies","volume":"2","author":"Hammitt","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2017.12.034_b0065","unstructured":"European Medicines Agency. EPAR Synflorix, pneumococcal polysaccharide conjugate vaccine (adsorbed), procedure no. EMEA\/H\/C\/000973-II\/0108; 2017. Available at: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000973\/WC500219552.pdf> [last accessed: 26.05.2017]."},{"key":"10.1016\/j.vaccine.2017.12.034_b0070","unstructured":"World Health Organization. WHO policy on the use of opened multi-dose vaccine vials (2014 Revision); 2014. Available at: <http:\/\/apps.who.int\/iris\/bitstream\/10665\/135972\/1\/WHO_IVB_14.07_eng.pdf> [last accessed: 26.05.2017]."},{"key":"10.1016\/j.vaccine.2017.12.034_b0075","first-page":"726","article-title":"Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries","volume":"81","author":"Drain","year":"2003","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2017.12.034_b0080","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2017.04.049","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: an open-label randomized controlled trial","volume":"35","author":"Idoko","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.034_b0085","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1586\/erv.09.113","article-title":"10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: synflorix","volume":"8","author":"Prymula","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.12.034_b0090","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1517\/14712598.8.4.503","article-title":"Clinical experience with DTPw-HBV and DTPw-HBV\/Hib combination vaccines","volume":"8","author":"Prymula","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2017.12.034_b0095","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/CVI.13.3.356-360.2006","article-title":"Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera","volume":"13","author":"Henckaerts","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.12.034_b0100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1128\/CVI.00289-09","article-title":"Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines","volume":"17","author":"Poolman","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.12.034_b0105","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.vaccine.2006.09.029","article-title":"Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children","volume":"25","author":"Henckaerts","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.034_b0110","unstructured":"World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. Proposed replacement of: TRS 927, Annex 2. Expert Committee on Biological Standardization, Geneva, Switzerland; 2009. Available at: <http:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/pneumo\/BS2108_Pneumo_recommendations.pdf> [last accessed: 26.05.2017]."},{"key":"10.1016\/j.vaccine.2017.12.034_b0115","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/INF.0b013e318199f8ef","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.12.034_b0120","unstructured":"European Medicines Agency. EPAR Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), procedure no. EMEA\/H\/C\/001104\/P46\/058; 2015. Available at: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/001104\/WC500191712.pdf> [last accessed: 26.05.2017]."},{"key":"10.1016\/j.vaccine.2017.12.034_b0125","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4161\/hv.19287","volume":"8","author":"Lalwani","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.12.034_b0130","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1128\/CVI.00068-14","article-title":"Randomized, open-label study of the impact of age on booster responses to the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in children in India","volume":"21","author":"Lalwani","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.12.034_b0135","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1186\/1471-2458-11-882","article-title":"Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial","volume":"11","author":"Dicko","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2017.12.034_b0140","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4161\/hv.22692","article-title":"Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children","volume":"9","author":"Dicko","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.12.034_b0145","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.vaccine.2017.03.071","article-title":"Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: a phase 2, randomized, controlled, observer-blind study","volume":"35","author":"Odutola","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.034_b0150","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1097\/INF.0b013e31822a8541","article-title":"Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants","volume":"30","author":"Kim","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.12.034_b0155","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/1471-2334-14-530","article-title":"A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia","volume":"14","author":"Lim","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.12.034_b0160","unstructured":"World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2016 global summary (Bangladesh, Schedule for pneumo_conj); 2016. Available at: <http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/countries?countrycriteria%5Bcountry%5D%5B%5D=BGD> [last accessed: 26.05.2017]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17317875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17317875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:23:43Z","timestamp":1759400623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17317875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0264410X17317875"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}